Company Overview of Highland Therapeutics Inc.
Highland Therapeutics Inc., through its subsidiary, develops and commercializes improved versions of existing drug products utilizing DELEXIS, a drug-delivery technology. Its pipeline products include HLD-200 (methylphenidate) and HLD-100 (amphetamine) that are novel formulations of the psychostimulants used to treat attention-deficit/hyperactivity disorder (ADHD) intended for nighttime dosing based on DELEXIS to provide a delay in the initial release of the active drug, followed by a period of extended release with the objective of providing control of ADHD symptoms immediately upon wakening and throughout the day. The company is headquartered in Toronto, Ontario, Canada.
101 College Street
Toronto, ON M5G 1L7
Key Executives for Highland Therapeutics Inc.
Highland Therapeutics Inc. Key Developments
Similar Private Companies By Industry
|1127466 B.C. Ltd.||Americas|
|9037136 Canada Inc.||Americas|
|AAA Heidelberg Inc.||Americas|
|Ab Biotech Inc.||Americas|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|NYC2012, Inc.||United States|
|Tax Management Inc||United States|
Sponsored Financial Commentaries
To contact Highland Therapeutics Inc., please visit www.highlandtherapeutics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.